Zyrova 5 Tablet contains Rosuvastatin 5mg, a potent HMG-CoA reductase inhibitor used primarily for the management of hypercholesterolemia and mixed dyslipidemia. By selectively inhibiting the enzyme HMG-CoA reductase, Zyrova 5 effectively reduces the synthesis of cholesterol in the liver, leading to decreased levels of low-density lipoprotein cholesterol (LDL-C) and total cholesterol, while modestly increasing high-density lipoprotein cholesterol (HDL-C). This lipid-modifying agent is indicated for primary and secondary prevention of cardiovascular disease, including atherosclerosis, by lowering elevated cholesterol levels in patients at risk. Zyrova 5 is also beneficial in reducing triglycerides and improving overall lipid profiles. It is typically prescribed alongside dietary modifications, exercise, and lifestyle changes for optimal therapeutic outcomes. The tablet is administered once daily, with or without food, and dosage adjustments should be based on patient response and tolerability. Monitoring of liver function tests and creatine kinase levels is recommended during therapy to detect potential adverse effects such as hepatotoxicity or myopathy. Zyrova 5 should be used cautiously in patients with pre-existing liver disease or renal impairment and is contraindicated during pregnancy and lactation. Adherence to prescribed therapy and regular follow-up are essential to maximize cardiovascular risk reduction.